Aragon Surgical: Start-Up Diversifies Early
This article was originally published in Start Up
Executive Summary
One of the golden rules of medical device start-ups is maintaining focus. That's why it was somewhat surprising to see that Aragon Surgical Inc., a start-up just emerging from stealth status, launched by veteran device investors Leslie Bottorff of Onset Ventures and David Douglass and John Maroney of Delphi Ventures, had recently completed an acquisition of a second product while its primary product still remains very much in the development stage.
You may also be interested in...
Start-Up Quarterly Statistics, Q1 2008
Start-Up analyzes fundraising and alliances among start-ups in the biopharmaceutical, medical device and in vitro diagnostics segments from January through March 2008. Data comes from Windhover’s Strategic Transactions Database.
Novasys: Using Clinical Trials to Drive Adoption for Incontinence
Novasys Medical is using radio frequency (RF) energy to treat stress urinary incontinence in women. The company chose to adopt a much more rigorous and expensive clinical trials strategy than was needed to gain FDA approval of its device. This approach flummoxed the FDA,, slowing approval of the company's IRenessaI system. Novasys is betting that the enhanced data collected from its clinical study will result in the company gaining faster reimbursement that it hopes will drive adoption.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”